To sum up the above progress of cancer-pathway targeting drugs in upstream and downstream KRAS, it is found that whether for longitudinal administration of AKT inhibitor in combination with PI3K inhibition, or for horizontal administration of BRAF inhibitor in combination with mTOR inhibitor 130, or vertical administration of downstream targeted in combination with upstream and middle targets, the clinical efficacy is superior to that of single administration and can achieve more lasting antitumor effect. The gene discussed is AKT1; the disease is cancer.